PacBio and ARUP Laboratories announced they are collaborating on a study intended to evaluate whether the solve rate for rare disease cases can be increased.
Deep Bio, a leading company in artificial intelligence (AI) cancer diagnostics, announced it obtained an approval from the University of IRB for a real-world implementation study.
About 200 research park and innovation district leaders from around the globe visited ARUP to hear how Research Park’s largest tenant has become a model for startups born in research institutions.
ARUP Laboratories’ intentional design of environmentally friendly features in its new state-of-the-art laboratory facility has already paid off in the form of a large rebate from Rocky Mountain Power, an electric utility company that services Utah, Idaho, and Wyoming.
Utah Rep. Burgess Owens visited ARUP Laboratories as part of a BioUtah BioHive tour of homegrown companies that have put Utah on the map as the center of innovation in the life sciences industry.
ARUP announced an investment in Techcyte Inc. as part of the company’s new $21 million funding round. This will enable Techcyte to expand the development team for its digital diagnostics platform.
Deep Bio announced a research collaboration agreement with ARUP Laboratories. Deep Bio’s AI-based prostate cancer diagnosis software will be used for the joint research.
GenomOncology announced that ARUP has chosen to extend its use of the GenomOncology (GO) Precision Oncology API Suite by integrating the GO Clinical Trial and Therapy Matching APIs into its workflows.
When global testing supply shortages halted diagnostic testing early in the COVID-19 pandemic, ARUP drew on reserves that have never been in short supply: the imagination and innovation of its medical laboratory scientists.
ARUP Laboratories and Techcyte, a leading developer of AI-based image analysis solutions for the diagnostics industry, have developed the world’s first AI-augmented ova and parasite detection tool.